{{Drugbox
| verifiedrevid = 444603089
| IUPAC_name = Diammine[(hydroxy-κO)acetato(2-)-κO]platinum
| image = Nedaplatin.png
| width = 120

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|nedaplatin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 95734-82-0
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
|  PubChem = 9796440
|  ChemSpiderID = 7972206
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8UQ3W6JXAN
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01416

<!--Chemical data-->
| chemical_formula =  
| C=2 | H=8 | As=  | N=2 | O=3 | Pt=1 
| molecular_weight = 303.17 g/mol
| smiles = C(C(=O)[O-])[O-].N.N.[Pt+2]
|  StdInChI = 1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1
|  StdInChIKey = GYAVMUDJCHAASE-UHFFFAOYSA-M

}}

'''Nedaplatin''' ([[International Nonproprietary Name|INN]], marketed under the tradename Aqupla) is a [[platinum-based antineoplastic]] drug which is used for cancer chemotherapy.<ref>{{cite journal | author = Apps, M. G., Choi, E. H. Y., Wheate, N. J. | year = 2015 | title = The state-of-play and future of platinum drugs | url = http://dx.doi.org/10.1530/ERC-15-0237 | journal = Endocrine-related Cancer | volume = 22 | issue = 4 | pages = 219–233 | pmid = 26113607 | doi = 10.1530/ERC-15-0237}}</ref>  The complex consists of [[transition metal ammine complex|two ammine ligands]] and the dianion derived from [[glycolic acid]].

Platinum-based drugs are widely employed as antineoplastic agents, especially [[cisplatin]] and [[carboplatin]].  Due to issues of their toxicity and number of cisplatin-resistant [[cancer cell]]s, other platinum derivatives have been developed.  Nedaplatin is one example of such new drugs.<ref>{{Cite journal|last=Johnstone|first=Timothy C.|last2=Park|first2=Ga Young|last3=Lippard|first3=Stephen J.|date=2014-01-01|title=Understanding and Improving Platinum Anticancer Drugs – Phenanthriplatin|journal=Anticancer research|volume=34|issue=1|pages=471–476|issn=0250-7005|pmc=3937549|pmid=24403503}}</ref>

==References==
{{Reflist}}
* {{ja icon}} [http://www.shionogi.co.jp/med/kihon/img/pdf/AQP.pdf Aqupla アクプラ] (PDF) Shionogi & Co. March 2007.

==External links==
* {{ja icon}} [http://www.shionogi.co.jp Official Shionogi & Co. Website]

{{Chemotherapeutic agents}}
{{Platinum compounds}}

[[Category:Platinum compounds]]
[[Category:Platinum-based antineoplastic agents]]
[[Category:Ammine complexes]]


{{antineoplastic-drug-stub}}